In this roundtable series, expert physicians look at the use of luspatercept-amt to treat anemia in patients with myelodysplastic syndromes throughout the course of treatment.
How the Frontline Indication for Luspatercept Impacts Anemia in MDS
Amer Zeidan, MBBS, discusses the recent expansion of the indication for luspatercept-amt to the frontline setting to treat anemia in patients with lower-risk myelodysplastic syndromes.
Subgroup Analyses of COMMANDS Trial Favor Luspatercept in MDS
Amer Zeidan, MBBS, discusses the primary end point and subgroup analyses performed on the COMMANDS trial of luspatercept-amt for treating anemia in patients with myelodysplastic syndromes.